Coagulation Studies, Factor V Leiden, and Anticardiolipin Antibodies in 40 Cases of Cerebral Venous Thrombosis
- 1 October 1996
- journal article
- case report
- Published by Wolters Kluwer Health in Stroke
- Vol. 27 (10) , 1724-1730
- https://doi.org/10.1161/01.str.27.10.1724
Abstract
Cerebral venous thrombosis (CVT) is an infrequent condition with a large variety of causes. However, in 20% to 35% of cases, no cause is found. We studied coagulation parameters, including activated protein C resistance associated with factor V gene mutation (factor V Leiden) and anticardiolipin antibodies, in a large series of patients with CVT with or without identified cause or risk factor. Forty patients (30 women and 10 men) aged 19 to 71 years (mean age, 36.2 years) with CVT diagnosed by angiography and/or MRI were studied 1 to 18 years after thrombosis. No known cause was found in 10 idiopathic cases. Coagulation studies included the following tests: fibrinogen, antithrombin, protein C, protein S, plasminogen, anticardiolipin antibodies, activated protein C resistance, and factor V Leiden. Six cases of thrombophilia (15%) were found: 1 protein C deficiency, 1 protein S deficiency, and 4 activated protein C resistance with heterozygous factor V Leiden mutation (10%). Only 1 case (protein S deficiency) was found in the group of 10 patients with idiopathic CVT. In the other 5, there was another cause or risk factor. Three patients (8%) had increased anticardiolipin antibodies: 1 with systemic lupus and 2 with primary antiphospholipid syndrome; 2 of these 3 patients also had factor V Leiden mutation. Although present in a number of CVT cases, acquired (anticardiolipin) or congenital varieties of thrombophilia (factor V Leiden being the most frequent) are almost invariably associated with other predisposing factors. This suggests that (1) these abnormalities should be looked for in patients with CVT, whether a cause is found or not, and (2) their presence should not deter the search for other potential causes. The detection of such abnormalities has major practical consequences on the long-term management of patients to prevent further thrombotic episodes.Keywords
This publication has 28 references indexed in Scilit:
- Development of resistance to activated protein C during pregnancyBritish Journal of Haematology, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Cerebral venous and sinus thrombosis – an updateEuropean Journal of Neurology, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Congenital protein C deficiency and superior sagittal sinus thrombosis causing isolated intracranial hypertension.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Cerebral sinus thrombosis in a patient with hereditary protein S deficiency: Case report and review of the literatureAnnals of Hematology, 1992
- Cerebral venous thrombosis in hereditary protein C deficiency.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Oral contraceptives reduce total protein S, but not free protein S.Thrombosis Research, 1987
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957